TrippBio is a biotech company focused on developing innovative antiviral treatments, particularly targeting serious respiratory viruses such as COVID-19, influenza, and RSV. Their lead product, PanCytoVir™, is currently undergoing clinical testing and aims to reduce disease severity, block virus replication, and mitigate hyper-inflammation. The drug operates through a unique mechanism that inhibits viral replication by targeting host proteins, specifically the organic anion transporter-3 (OAT3) gene, which is crucial for flu virus replication. This approach not only aims to prevent drug resistance but also positions PanCytoVir™ as a potential broad-spectrum therapeutic option.

In addition to its antiviral properties, PanCytoVir™ has demonstrated potential anti-inflammatory benefits by modulating the expression of ACE2 and targeting the pannexin-1 (PANX1) gene. This modulation may help reduce airway inflammation associated with viral infections. TrippBio's commitment to low-risk, high-efficacy treatments is evident in their ongoing research and clinical trials, which include a randomized study evaluating the efficacy of PanCytoVir™ for non-hospitalized COVID-19 patients. The company is also exploring the drug's effectiveness against influenza and RSV, aiming to provide much-needed therapeutic options in these areas where current treatments are limited.

United States

TrippBio is a biotech company that identifies new applications for existing drugs as a way to treat viruses like SARS-CoV-2, which causes COVID-19.

TrippBio

Company Details